The UK's drug regulator approved CStone Pharmaceuticals' (HKG:2616) sugemalimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC).
Sugemalimab, in combination with platinum-based chemotherapy, has been granted authorization as first-line therapy for adult patients suffering from NSCLC without EGFR-sensitive mutations or ALK, ROS1, and RET genomic alterations.
This marks the second overseas approval for sugemalimab following its recent authorization by the European Commission, the drugmaker said in Thursday filing with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.